Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
about
Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaMedical treatment of renal cancer: new horizonsDo renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studiesPatients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities.Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.Safety of available treatment options for renal cell carcinoma.Sunitinib side effects as surrogate biomarkers of efficacy.Renal cell carcinoma: new insights and challenges for a clinician scientist.Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.Renin angiotensin system deregulation as renal cancer risk factor.Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.Individualized dosing with axitinib: rationale and practical guidance.Medication use and kidney cancer survival: A population-based study.Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study.Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development.Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity
P2860
Q28066747-BE669219-14F4-40A2-A02A-6FB121D57550Q28073174-42E3D7C4-2816-4AFA-9496-B3F2B56487F2Q30235047-8BD7D108-091C-4E7D-8706-989F90FCD2FBQ36600872-6F0CF6D4-2AA7-4B12-8570-BA147EE81C2FQ38696205-D0EEC057-0DBB-4753-9AF4-5EA53C1C2645Q38824719-E8F1075B-1B29-4574-9C4E-B103B5DB3E18Q39092937-EEE365C7-4539-463A-B100-1048A8ED3390Q39222755-B54DC5A9-3437-49DE-9978-44B9419D9576Q41035635-BC5FAF02-5DCF-4FFC-B104-01A06ED5A033Q41410574-57263048-0D45-4849-88DE-F08075F0F8BFQ41573990-AAFCA354-839D-4A71-8E4B-20646561B750Q45073137-A04C9B3B-F571-4FE2-AD32-801DC045D5B5Q47094986-B06C7A78-DFAC-4F05-9212-E1AE8AF13500Q47106953-75333745-B71B-4A5A-82C6-5F53FEFDBE16Q47271327-65F56967-EA37-499B-BF39-2D65E7218E23Q47333254-4595FED0-52CB-407E-8717-777E0A7E27B3Q47863448-4E5160D6-BA0E-4B46-9130-6DB15FFAF740Q49635743-3CC988F8-F509-4C57-8E22-0178CA0ACEBAQ52808495-0E601A7C-5A3C-4C93-8D3F-0DDB82FB24DEQ59125636-7935328E-FAF8-4E7D-9942-C938A78C6ACE
P2860
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Hypertension and angiotensin s ...... tastatic renal cell carcinoma.
@en
Hypertension and angiotensin s ...... tastatic renal cell carcinoma.
@nl
type
label
Hypertension and angiotensin s ...... tastatic renal cell carcinoma.
@en
Hypertension and angiotensin s ...... tastatic renal cell carcinoma.
@nl
prefLabel
Hypertension and angiotensin s ...... tastatic renal cell carcinoma.
@en
Hypertension and angiotensin s ...... tastatic renal cell carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Hypertension and angiotensin s ...... tastatic renal cell carcinoma.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDV147
P577
2015-03-20T00:00:00Z